Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes

被引:138
作者
Guenther, JM
Hansen, NM
DiFronzo, LA
Giuliano, AE
Collins, JC
Grube, BL
O'Connell, TX
机构
[1] Kaiser Los Angeles, Med Ctr, Los Angeles, CA USA
[2] St Johns Hosp, Joyce Eisenberg Keefer Breast Ctr, Santa Monica, CA USA
关键词
D O I
10.1001/archsurg.138.1.52
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hypothesis: Sentinel node (SN) biopsy for breast cancer enhances staging sensitivity, often demonstrating only micrometastases (<2 mm) or isolated, keratin-positive cells. When SN metastasis is present, the value of additional axillary dissection is unclear and not all patients benefit from axillary lymph node dissection (ALND). Design: Prospective cohort study, median 32-month follow-up. Setting: Multidisciplinary breast cancer centers. Patients: Forty-six women having SN metastases diagnosed between May 1, 1996, and September 1, 2001, who refused ALND or were recommended to omit ALND owing to serious comorbid conditions. Interventions: Isosulfan blue dye-directed SN biopsy. Axillary lymph node dissection was not performed. Standard breast irradiation was given. Adjuvant systemic therapy was provided as determined by an oncologist. Interval clinical evaluation was performed. Main Outcome Measure: Axillary and systemic failure rates. Results: Mean patient age was 61.6 years (age range, 36-92 years). Mean tumor size was 1.65 cm (range, 0.4-5.5 cm). Thirty-five (76%) of 46 tumors were ductal carcinomas and 39 (87%) of 45 were estrogen receptor-positive. A mean of 2.6 SNs were identified (median, 2; range, 1-7). Thirty-nine patients (85%) had a single positive SN; the remaining 7 patients (15%) had 2 positive SNs. Seven patients (15%) had macrometastases (>2 mm); 16 (35%) had micrometastases (<2 mm); and 23 (50%) had cellular metastases. Only 16 positive SNs (35%) were seen on hematoxylin-eosin staining, while 30 SNs (65%) had positive inummohistochemical staining. There have been no axillary recurrences. One patient (2%) developed distant metastases during follow-up (range, 4-61 months). Conclusions: Patients with SN metastases who did not have ALND had a low incidence of regional failure. To confirm this observation, we suggest that patients with SN metastases; are ideal candidates for trials evaluating the necessity of ALND.
引用
收藏
页码:52 / 56
页数:5
相关论文
共 27 条
[1]   Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J].
Albertini, JJ ;
Lyman, GH ;
Cox, C ;
Yeatman, T ;
Balducci, L ;
Ku, NN ;
Shivers, S ;
Berman, C ;
Wells, K ;
Rapaport, D ;
Shons, A ;
Horton, J ;
Greenberg, H ;
Nicosia, S ;
Clark, R ;
Cantor, A ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1818-1822
[2]  
BARTLETT K, 1987, LANCET, V2, P171
[3]  
CABANAS RM, 1977, CANCER, V39, P456, DOI 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO
[4]  
2-I
[5]   VALUE OF AXILLARY DISSECTION IN ADDITION TO LUMPECTOMY AND RADIOTHERAPY IN EARLY BREAST-CANCER [J].
CABANES, PA ;
SALMON, RJ ;
VILCOQ, JR ;
DURAND, JC ;
FOURQUET, A ;
GAUTIER, C ;
ASSELAIN, B .
LANCET, 1992, 339 (8804) :1245-1248
[6]   Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis [J].
Chu, KU ;
Turner, RR ;
Hansen, NM ;
Brennan, MB ;
Giuliano, AE .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (08) :756-761
[7]   Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? [J].
Chu, KU ;
Turner, RR ;
Hansen, NM ;
Brennan, MB ;
Bilchik, A ;
Giuliano, AE .
ANNALS OF SURGERY, 1999, 229 (04) :536-541
[8]   Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J].
Fisher, B ;
Brown, A ;
Mamounas, E ;
Wieand, S ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Fisher, ER ;
Wickerham, DL ;
Wolmark, N ;
DeCillis, A ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) :2483-2493
[9]  
FISHER B, 1977, CANCER-AM CANCER SOC, V39, P2827, DOI 10.1002/1097-0142(197706)39:6<2827::AID-CNCR2820390671>3.0.CO
[10]  
2-I